Arwen: Sorry you took my post badly as no harm and no sarcasm intended. My LOL was simply commiseration and certainly not laughing at you. I can take your comments and criticism without need or desire for vengeance.
Sometimes I win, sometimes I lose. Sometimes you win, sometimes you lose. Thats the way it goes. When I say *good luck* to you what I mean is that I hope you win more than you lose. I only wish you the best.
Earlier this week share of Exelixis skyrocketed after the company said its most advanced experimental drug more than doubled the amount of survival time of patients with a type of thyroid cancer. Exelixis said it will meet the Food and Drug Administration, and will ask if it can submit its application for approval of cabozantinib piece-by-piece instead of waiting to file its application all at once. The company plans to finish its application in the first half of 2012. The FDA has agreed to approve cabozantinib if data shows it improves patients' survival.
The new report states Nov. as the beginning time that they will review with the FDA. The results in the new report is even more mind blowing. It is 20 pages of data, so I will post some of the important parts. It also states for fast track studies for six other forms of cancer. Their trails are being conducted in 30 of the best cancer hospitals worldwide. Most from Boston to San Francisco to Sacramento. Doctors feel that they hit the Holy Grail. The best cancer treatment to date. Patients look, feel and are very happy. Remember that DNDN went from 2 to 65. The treatment drugs from EXEL will cost a lot less. Insurance will cover. GL.